Any feedback?
Literature summary for 3.1.6.13 extracted from
- The effect of recombinant human iduronate-2-sulfatase (idursulfase) on growth in young patients with mucopolysaccharidosis type II (2014), PLoS ONE, 9, e85074.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | effects of enzyme replacement therapy with iduronate 2-sulfatase on growth in young patients with mucopolysaccharidosis type II. Patients in group 1 received intravenous idursulfase at a standard dose of 0.58 mg/kg weekly for 52-288 weeks. The course of average growth curve for group 1 is very similar to growth pattern in group 2 naive to the enzyme. The average value of body height in subsequent years in group 1 is a little greater than in group 2, however, the difference is not statistically significant. In studied patients with mucopolysaccharidosis type II, idursulfase does not appear to alter the growth patterns | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| elaprase | - |
Homo sapiens |
| idursulfase | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
